Literature DB >> 9692167

Long-term effect of mass diethylcarbamazine chemotherapy on bancroftian filariasis, results at four years after start of treatment.

D W Meyrowitsch1, P E Simonsen.   

Abstract

The long-term effect of 4 strategies for control of bancroftian filariasis using mass diethylcarbamazine (DEC) chemotherapy was assessed and compared in 4 endemic communities in Tanzania over a period of 4 years. The strategies were the standard 12 d treatment (strategy I), semi-annual single dose treatment (strategy II), monthly low dose treatment (strategy III), and DEC-medicated salt treatment (strategy IV). Treatment was given only during the first year. All strategies resulted in considerable reductions in microfilaraemia, with maximum effects occurring 1-2 years after start of treatment. At 2 years, the greatest reductions were seen for strategies III and IV, followed by strategy II and finally strategy I. The overall performance of the 4 strategies evaluated over the 4 years period followed the same sequence. Between the 2 years and 4 years follow-up surveys, a significant increase in microfilarial (mf) burden occurred in all 4 communities, but the mf geometric mean intensities (GMI) remained low. Thus, in individuals who were microfilaraemic before treatment, the rates of microfilaraemia were 66%, 44%, 34% and 43%, and the mf GMIs were 6.8%, 3.3%, 0.5% and 0.7%, of pre-treatment level, 4 years after start of treatment with strategies I, II, III and IV, respectively. Most individuals who developed microfilaraemia between the 2 years and 4 years follow-up surveys had been microfilaraemic before the start of treatment. Hence, the rate of development of microfilaraemia was much higher (18 times on average in the 4 communities) among those who were microfilaraemic before treatment than among those who were amicrofilaraemic. The long-lasting effect of treatment adds a promising potential to the use of mass DEC chemotherapy for the control of bancroftian filariasis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9692167     DOI: 10.1016/s0035-9203(98)90973-7

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  7 in total

Review 1.  Diurnally subperiodic filariasis in India-prospects of elimination: precept to action?

Authors:  A N Shriram; K Krishnamoorthy; B P Saha; Avijit Roy; V Kumaraswami; W A Shah; P Jambulingam; P Vijayachari
Journal:  Parasitol Res       Date:  2011-02-01       Impact factor: 2.289

2.  Unfulfilled potential: using diethylcarbamazine-fortified salt to eliminate lymphatic filariasis.

Authors:  Patrick Lammie; Trevor Milner; Robin Houston
Journal:  Bull World Health Organ       Date:  2007-07       Impact factor: 9.408

3.  Elimination of diurnally sub-periodic Wuchereria bancrofti in Andaman and Nicobar Islands, India, using mass DEC-fortified salt as a supplementary intervention to MDA.

Authors:  A N Shriram; Addepalli Premkumar; K Krishnamoorthy; Amitabha De; S K Paul; S Subramanian; P Vijayachari; P Jambulingam
Journal:  Parasitol Res       Date:  2020-03-26       Impact factor: 2.289

4.  A low-tech analytical method for diethylcarbamazine citrate in medicated salt.

Authors:  Abigail Weaver; Patrick Brown; Shannon Huey; Marco Magallon; E Brennan Bollman; Dominique Mares; Thomas G Streit; Marya Lieberman
Journal:  PLoS Negl Trop Dis       Date:  2011-02-08

5.  Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature.

Authors:  David G Addiss; Molly A Brady
Journal:  Filaria J       Date:  2007-02-15

6.  Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease.

Authors:  K D Ramaiah; Eric A Ottesen
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

7.  Assessing endgame strategies for the elimination of lymphatic filariasis: A model-based evaluation of the impact of DEC-medicated salt.

Authors:  Morgan E Smith; Brajendra K Singh; Edwin Michael
Journal:  Sci Rep       Date:  2017-08-07       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.